Stay updated with breaking news from Jongyoon Han. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Learn how implementing a SMART approach in stem cell manufacturing can lead to improved efficiency and cost reduction for the production of mesenchymal stem cells (MSCs) used in the treatment of osteoarthritic and autoimmune conditions.
A tiny device built by scientists at MIT and the Singapore-MIT Alliance for Research and Technology could be used to improve the safety and effectiveness of cell therapy treatments for patients suffering from spinal cord injuries.
A tiny microfluidic device can improve cell therapy techniques for spinal cord injury patients. The device can remove a large percentage of stem cells that have not yet fully become spinal cord cells, which could potentially form tumors after being transplanted into a patient.
LiveNews Provides news reports of information as it happens in real time of politics, business, the economy and also reports on global issues and events from a New Zealand viewpoint.
Researchers from the Critical Analytics for Manufacturing Personalized-Medicine (CAMP) Interdisciplinary Research Group (IRG) of Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, in collaboration with the Agency for Science, Technology and Research (A*STAR) Bioprocessing Technology Institute (BTI) and National University Health System (NUHS), have developed a groundbreaking technology capable of extracting mesenchymal stem cells (MSCs) directly from pure bone marrow – also known as bone marrow aspirate (BMA), a pivotal source of MSCs – wi...